Vyome Holdings, Inc. (HIND) Fair Value 2026

HIND · Pharmaceutical Preparations ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.3 /10

32 fundamental signals · 12 models active

Value Trap Risk

LOW (26/100)

Quick Summary — As of 2026-07-15, Vyome Holdings, Inc. (HIND) trades at $2.27, approximately 331% above CirclFi’s Bayesian DCF fair value of $0.53. QOC: 4.3/10. Value Trap Risk: 26/100 (LOW). 12/13 models active.

Key Facts

Ticker
HIND
Price
$2.27
Quality Score
4.3/10
Value Trap Risk
26/100
Models Active
12/13
Last Updated
Strength: 12 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 4.3/10 signals weak fundamentals

Is Vyome Holdings, Inc. (HIND) Undervalued or Overvalued in 2026?

According to CirclFi’s 12-model valuation engine, Vyome Holdings, Inc. (HIND) appears overvalued as of : the median of 12 independent fair value estimates is $0.65, 71.4% below the current price of $2.27. Estimates range from $0.17 to $12.45. HIND scores 4.3/10 on fundamental quality and 26/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Vyome Holdings, Inc. Stock in 2026? →

Valuation Matrix

12 Intrinsic Value Models vs. Current Price ($2.27)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $0.53 -76.8%
Earnings Power Value
Low Conviction
 $0.39 -83.0%
CUCE Ensemble
Low Conviction
 $0.77 -65.9%
First Chicago
Low Conviction
 $0.47 -79.3%

Unlock the Full Matrix

Access 8 additional models including EROIC Spread, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 12 Models →

Cancel anytime · No contracts · Instant access

What Is Vyome Holdings, Inc. (HIND) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Vyome Holdings, Inc. at its current price of $2.27. The composite intrinsic value is estimated at $2.20 (-3.2% average return), with 8 models flagging overvaluation risk. The most optimistic model, RCMH-DCF, places fair value at $12.45 (+448.6%), while EROIC — the most conservative — estimates $0.17 (-92.4%). This +541.0% gap reflects genuine analytical uncertainty about Vyome Holdings, Inc.'s intrinsic worth.

What Do the Models Say About HIND?

12 of 13 models are currently active for HIND. Of these, 2 models suggest upside while 10 models suggest overvaluation. The Bayesian DCF estimates HIND's intrinsic value at $0.53, implying -76.8% downside from the current price. See which stocks rank higher →

How Does HIND Rank in Pharmaceutical Preparations?

Among 431 Pharmaceutical Preparations stocks, HIND ranks #302 by Quality of Company score. CirclFi's QOC score of 4.3/10 evaluates 32 fundamental signals. A score of 4.3 reflects mixed fundamentals.

See all Most Undervalued Pharmaceutical Preparations Stocks →

As a pharmaceutical industry, Vyome Holdings, Inc. operates in a sector where R&D productivity ratio is a critical driver of valuation. Investors evaluating HIND should weigh these sector-specific dynamics alongside our model-derived fair values.

Is HIND a Value Trap?

CirclFi's Value Trap algorithm assigns HIND a score of 26/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

12 of 13 models are active for Vyome Holdings, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Vyome Holdings, Inc.'s fundamental quality profile registers 4.3/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +541.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every HIND valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across HIND's 12 active models, average confidence is 21%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Vyome Holdings, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Pharmaceutical Preparations Stocks Should You Also Analyze?

8 related Pharmaceutical Preparations stocks with 13-model coverage

AZNAstraZeneca PLCQOC 10.0CPRXCatalyst Pharmaceuticals, Inc.QOC 10.0HRMYHarmony Biosciences Holdings, IQOC 10.0NVONovo Nordisk A/SQOC 10.0SIGASIGA Technologies Inc.QOC 10.0UTHRUnited Therapeutics CorporationQOC 10.0ZTSZoetis Inc.QOC 10.0RDYDr. Reddy's Laboratories LtdQOC 9.9

Read investment analysis: AZN · CPRX · HRMY · NVO · SIGA

See all Pharmaceutical Preparations stocks ranked →

Frequently Asked Questions About Vyome Holdings, Inc.

What is Vyome Holdings, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Vyome Holdings, Inc. (HIND) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $0.53. The Quality of Company score is 4.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is HIND overvalued or undervalued right now?

At $2.27, 2 of 12 active models suggest HIND may be undervalued, while 10 indicate potential overvaluation. The median of all 12 fair value estimates is $0.65, 71.4% below the current price of $2.27 — a consensus view that HIND is overvalued. The assessment depends on which methodology best fits Vyome Holdings, Inc.'s business model in Pharmaceutical Preparations.

What does a Quality of Company score of 4.3 mean for HIND?

Vyome Holdings, Inc.'s QOC of 4.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on HIND?

CirclFi analyzes HIND with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 12 of 13 are active for this stock. Read the full methodology →

Is HIND a value trap in 2026?

Vyome Holdings, Inc.'s Value Trap score is 26/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 12-model valuation engine, Vyome Holdings, Inc. (HIND) has a median fair value of $0.65 — 71.4% below the current price of $2.27 — as of 2026-07-15.” Source: circlfi.com/stock/HIND/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 12 mathematical frameworks give you clarity on HIND.

Unlock All 12 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access